We study the combined impact that all-or-none compliance and subsequent missing outcomes can have on the estimation of the intention-to-treat effect of assignment in randomised studies. In this setting, a standard analysis, which drops subjects with missing outcomes and ignores compliance information, can be biased for the intention-to-treat effect. To address all-or-none compliance that is followed by missing outcomes, we construct a new estimation procedure for the intention-to-treat effect that maintains good randomisation-based properties under more plausible, nonignorable noncompliance and nonignorable missing-outcome conditions: the 'compound exclusion restriction' on the effect of assignment and the 'latent ignorability' of the missing data mechanism. We present both theoretical results and a simulation study. Moreover, we show how the two key concepts of compound exclusion and latent ignorability are relevant in more complicated settings, such as right censoring of a time-to-event outcome.
I
Randomised experiments with human subjects often suffer from two major complications, namely noncompliance to treatment assignment and missing outcomes. In general, noncompliance is selective (The Coronary Drug Project Research Group, 1980) in the sense that noncompliers and compliers generally differ in background characteristics. Moreover, missing outcomes, often caused by refusal or loss to follow-up, may also be selective in the analogous sense (Farwell et al., 1990) . These complications are rarely fully within the experimenter's control, and there is currently substantial awareness among researchers that such complications in a study compromise the ability to draw clear conclusions.
We assume a simple two-arm randomised experiment comparing a new versus a standard treatment, with access to the new, experimental treatment only in the new treatment arm and all-or-none compliance. A special case is the Zelen randomised single-consent design (Zelen, 1979 (Zelen, , 1990a , where those assigned standard treatment cannot receive the new treatment, and those assigned the new treatment either receive it or the standard treatment.
F

2·1. T he data
In order to address better the different sources of missing information in this problem, we first define potential outcomes separately from a sampling scheme or probabilistic assignment mechanism, an approach dating back to Neyman (1923) in the context of perfect randomised trials, formalised and extended to nonrandomised studies in Rubin (1974 Rubin ( , 1978 , and referred to as the Rubin causal model (Holland, 1986) . Consider a large population of individuals {v}, each of which can potentially participate in a study and be assigned a treatment z, with z=1 for new, 0 for standard. For each individual v, let D(v, z) be the actual treatment received, 1 for new, 0 for standard, if that individual is Intention-to-treat analysis assigned treatment z. Also let Y (v, z) and R(v, z) be, respectively, the outcome and indicator for response, equal to 1 for response, 0 for nonresponse, on outcome Y, if individual v is assigned treatment z.
A simple random sample of n subjects from {v}, v 1 , . . . , v n , say, comprises the participants in the study. Each subject is then randomly assigned treatment arm Z i , 1 for new, 0 for standard, where for simplicity Z i (i=1, . . . , n) are essentially independent, identically distributed Bernoulli variables. Then the observable vectors
. . , n) are essentially independent and identically distributed replicates with respect to the random sampling-random assignment mechanism, and will be denoted by
We assume that the observed data from the study include (i) the treatment assignments {Z i }; (ii) the actual treatments received {D i }, where by assumption D i =0 if Z i =0; and (iii) the indicators for whether or not outcomes are observed, {R i }, where outcome Y i is observed if R i =1 and missing if R i =0. Hence, the observed data are
Let Y 9 z )E{Y (v i , z)} be the expected outcome when all units are assigned z, for z=0, 1, where the probability measure is the one induced by the random sampling from {v}. We focus on estimating the intention-to-treat treatment effect on the means of Y in {v}, given by
A more specific question is whether or not the intention-to-treat null hypothesis of no effect of assignment on the outcomes, H 0 : Y 9 1 −Y 9 0 =0, is plausible. The methods that we will discuss can formally be applied within the levels of other pretreatment covariates, but, to focus on conceptual issues, we assume that no covariate is recorded, or that we are already within a cell defined by such covariates.
2·2. Role of treatment-noncompliance with missing outcomes Let U(v))D(v, 1) be the received treatment for individual v when assigned the new treatment, where U i )U(v i ) for the ith study individual v i . Since U i =1 if person v i would comply under both treatment assignments, we refer to such a person as a 'complier', and, because U i =0 if person v i would never take the new treatment, no matter what the assignment, we refer to such a person as a 'never-taker'; see the Harvard Institute of Economic Research Discussion paper #1676 by G. W. Imbens and D. B. Rubin 'Causal inference with instrumental variables'. By definition, the quantity U(v) is fixed for individual v, and therefore it is a covariate, the true compliance status covariate (Angrist, Imbens & Rubin, 1996; Rubin, 1998) , though it is only partially observed in the sample;
Despite being missing in the standard treatment arm, by randomisation, the covariate U i has the same distribution in the standard treatment arm as in the new treatment arm in the study; see Fig. 1 
In the presence of subsequent missingness of the outcome Y i , indicated by R i =0, a strict intention-to-treat analysis cannot be done and the role of the compliance covariate U i is critical. To describe this role, consider for the moment an investigator who, hypothetically, knows the compliance covariate values U i for all subjects, that is, whether each subject would comply with the new treatment, a complier, or not, a never-taker, under assignment to take it. Researchers have expressed the desire to have known this information, e.g. Schechtman & Gordon (1988) , and consideration of this case suggests how to analyse the data without such information.
With U i fully observed, the investigator would have a covariate, U i , and therefore would have the following main options. Approach 1. Ignore the fully observed covariate, and compare respondents between randomised arms. In order for this approach to be correct, response R i should be independent of outcomes Y i before conditioning on the covariates U i , as when the missing Y values are missing completely at random (Little & Rubin, 1987, Ch. 1) .
Approach 2. Do separate analyses for compliers, U i =1, and for never-takers, U i =0. Then, combine these analyses, weighted by the proportions of compliers and never-takers since the goal is the overall intention-to-treat effect. This approach allows for response R i to be ignorable (Rubin, 1976) or, essentially here, independent of outcome Y i after, but not necessarily before, conditioning on the compliance covariates U i .
In practice it may be that neither of the above two approaches is correct, but this is not testable. To avoid confounding, it is general practice when confronted with missing outcomes first to condition on important covariates before assuming independent nonresponse. For example, we assume we are already within a cell defined by all other observed covariates, because such conditioning is standard. The clinical trials literature typically regards the latent compliance covariate U i to be important in the sense of being associated with both (i) background characteristics of health related to the outcome Y i , as well as (ii) response R i ; see for example The Coronary Drug Project Research Group (1980), Schechtman & Gordon (1988 ), Farwell et al. (1990 , Gordon & Schechtman (1990) and Intention-to-treat analysis Zelen (1990b). Therefore, the investigator with knowledge of all values of U i should regard Approach 2 as more reliable than Approach 1, because Approach 2 conditions on a potentially important covariate whereas Approach 1 does not.
Hence, to formalise this conclusion, we assume that, if U i were fully observed, we would accept ignorability of the missing data mechanism for Y i only after conditioning on U i . That is, we would accept Assumption 1.
Assumption 1: L atent ignorability. Potential outcomes and associated potential nonresponse indicators are independent within each level of the latent compliance covariate:
(a) when assigned new treatment,
( b) when assigned standard treatment,
Assumption 1 is related to missing-data mechanisms discussed by Baker (1994) in the context of incomplete covariates.
In the randomised trial, Assumption 1 implies that
where, here and in the sequel, the probability measure is the one induced by the random sampling and random assignment mechanism of the trial.
To address complications because the true compliance covariate is missing, we also make Assumption 2.
Assumption 2: Compound exclusion restriction for never-takers. If, for individual v,
Since for the never-takers the treatment actually received would be the same no matter what their treatment assignment, the intervention of assignment within the study is arguably of little relevance to them. Consequently, Assumption 2 asserts that, for the nevertakers, who are defined by the covariate U(v)=0, there is no effect of assignment on either their outcomes Y (v, z) or their response behaviours R(v, z). Although Assumption 2 may not be true, it is expected to hold approximately in double-blind trials or often when the outcome is measured long after final exposure to the new treatment for the nevertakers has occurred. Assumption 2 is closely related to 'exclusion restriction' assumptions in the traditional instrumental variables approach (Durbin, 1954; Goldberger, 1972; Angrist et al., 1996) , also used in biomedical applications, e.g. Baker & Lindeman (1994) and Sommer & Zeger (1991) , and which apply to outcomes, Y. Our use of 'compound' implies that the exclusion restriction applies to both the values of Y and the missingness of Y.
An immediate consequence of Assumption 2 is that, in the randomised trial,
Under Assumptions 1 and 2, the outcomes Y i and response indicators R i are generally 370 C E. F  D B. R correlated in the standard treatment arm because no U i is observed there. That is, for those units assigned standard treatment, there is no set of observed data on which to condition to make nonresponse independent of outcome. In the terminology of Rubin (1976), the missing outcomes {Y i : R i =0} are generally not missing at random, and so the nonresponse is nonignorable.
Under Assumptions 1 and 2, we next show that the respondent-based intention-to-treat estimator for Y 9 1 −Y 9 0 is generally biased even under H 0 . Consistent estimation for Y 9 1 −Y 9 0 under Assumptions 1 and 2 will be discussed in § 3.
2·3. Bias of respondent-based intention-to-treat estimator for intention-to-treat eVect From the observed data (2·1), standard respondent-based intention-to-treat analysis disregards the actual treatment data {D i } and constructs an estimator for Y 9 1 −Y 9 0 based on the respondents within each assignment arm using
the difference in sample average outcomes among respondents at each assignment arm:
where I(.) is the indicator function. For technical reasons, assume E(Y 2 i ) is finite, and let
, the probability limit of Y B obs z for z=0, 1. Under Assumptions 1 and 2, however, estimator (2·3) is biased in our setting because, generally, Y 9 obs 1 −Y 9 obs 0
the mean outcomes and response probabilities, respectively, within levels of the true compliance covariate and assignment arms, and let U 9 )E(U i ), the proportion of compliers. Finally, let R 9 z )E(R i | Z i =z), the marginal response rates within assignment arms. We then have the following result. R 1. Under Assumptions 1, 2, and H 0 ,
Proof. Under Assumption 2, the compound exclusion restriction, there is no effect of assignment for the never-takers, (Y 9 0,0 , R 9 0,0 )=(Y 9 0,1 , R 9 0,1 ), and so we will denote by (Y 9 0,1 , R 9 0,1 ) the never-taker average outcome and response probability for both treatment assignment arms. Under Assumption 1, latent ignorability, then
From Bayes' theorem, we have
With U 9 >0 we now assume that H 0 is true or, equivalently, Y 9 1,1 =Y 9 1,0 , by the com-Intention-to-treat analysis pound exclusion restriction. If we use (2·5) in (2·4), and with the mixture R 9 z = U 9 R 9 1,z +(1−U 9 )R 9 0,1 , Result 1 follows after some algebra. %
In Result 1, Y 9 obs 1 −Y 9 obs 0 is not zero unless either the response rates for compliers, R 9 1,1 and R 9 1,0 , are the same, or the mean outcomes between compliers and never-takers, Y 9 1,1 and Y 9 0,1 , are the same, or R 9 0,1 =0 so that all never-takers are nonrespondents. Consequently, under Assumptions 1 and 2 and the null hypothesis H 0 , the respondentbased intention-to-treat estimator (2·3) is generally biased for the intention-to-treat effect. Although intention-to-treat analysis is generally promoted, in contrast to naive and biased 'as-treated' and 'per-protocol' analyses, to avoid the heterogeneity of differential characteristics between compliers and never-takers, it is this same heterogeneity that may render the missing outcomes nonignorable and hence respondent-based intention-to-treat analysis incorrect. Better procedures, however, do exist. In § 3 we construct an estimator that is randomisation-based consistent for Y 9 1 −Y 9 0 under Assumptions 1 and 2.
3. E       Each assignment arm comprises a mixture of never-takers and compliers, so
Under the compound exclusion restriction, Y 9 0,1 =Y 9 0,0 , and therefore (2·2) can be written as
where Y 9 1,1 −Y 9 1,0 is the effect of assignment on the compliers; see also Angrist et al. (1996) . In the new treatment arm, all true compliance covariates U i are observed and equal in value to D i . By virtue of the latent ignorability assumption, the stratified estimator
is then consistent for Y 9 1,1 by the law of large numbers. The estimation of U 9 and Y 9 1,0 in (3·1) requires only easily estimable quantities. The key idea in estimation is to realise first that, by randomisation, the mixing proportions of never-takers, U i =0, and compliers, U i =1, are directly estimable from the new treatment assignment arm where the covariates U i are fully observed. Moreover, because of the compound exclusion restriction, for never-takers response R i is identical under both assignment arms. Hence, in the new treatment arm, Z i =1, the units can be partitioned into the following: compliers with Z i =1, U i =1; responding never-takers with Z i =1, U i =0 and R i =1; and nonresponding never-takers with Z i =1, U i =0 and R i =0. Thus the proportions of these three types in the population are directly estimable from observed data in the new treatment arm. Moreover, the mean outcomes for responding never-takers, assigned new or standard treatment, Y 9 obs 0,1 , are directly estimable in the new treatment arm. Including latent ignorability implies that Y 9 obs 0,1 =Y 9 0,1 . Latent ignorability analogously would allow direct estimation of the compliers' mean outcome Y 9 1,0 when assigned standard treatment if the covariates U i were observed in that arm. Although this specific information is not available, the mixing proportions of compliers, responding never-takers and nonresponding never-takers along with Y 9 0,1 and the observed Y 9 obs 0 are enough to identify the compliers' mean outcome Y 9 1,0 . The following lemma, proved in the Appendix, allows a method of moments estimator to be constructed for Y 9 1,0 that can be considered an extension of the econometric instrumental variables estimator (Angrist et al., 1996) . L 1. Under Assumptions 1, 2, and with U 9 >0,
The estimator Y B 1,0 we consider for Y 9 1,0 is obtained by using the sample analogues for the quantities in the right-hand side of (3·2). Specifically, define U B )W D i Z i /W Z i and
, for z and u in {0, 1}, and
The following result, proved in the Appendix using the delta method, forms a basis for inference about Y 9 1 −Y 9 0 .
R 2. Under Assumptions 1, 2 and with U 9 >0,
d=[−R 9 0 R 9 0,1 (Y 9 obs 0 −Y 9 0,1 )w2, −R 9 0,1 (1−U 9 )w, R 9 0 (Y 9 obs 0 −Y 9 0,1 )(1−U 9 )w2, −R 9 0,1 (Y 9 obs 0 −Y 9 0,1 )(1−U 9 )w2, R 9 0 w]∞, w={R 9 0 −R 9 0,1 (1−U 9 )}−1.
By standard results, nD(Y
. Furthermore, it can be shown that the two standardised estimators of interest, nD(Y B 1,0 −Y 9 1,0 ) and nD(Y B 1,1 −Y 9 1,1 ), are asymptotically independent, by a Taylor series expansion and Slutsky's theorem. By defining V B 0,1 , V B 1,1 and V B obs 0 to be the usual sample estimates for V 0,1 , V 1,1 , and V obs 0 respectively, and with d A , v A and q A the resulting sample analogues of d, v and q, it is a direct consequence of Result 2 and Slutsky's theorem that
), it can be easily shown using the Taylor expansion in the Appendix that
(3·4) Intention-to-treat analysis in distribution as n 2. Therefore, if we use the estimator Y B 1 −Y B 0 , confidence intervals for the intention-to-treat estimand, Y 9 1 −Y 9 0 , can be constructed based on the normal approximation (3·4). In the following section we examine some finite sample properties of this estimator, and compare it with the standard intention-to-treat estimator (2·3) under various conditions. Although under our assumptions the estimator (2·3) is theoretically inconsistent for Y 9 1 −Y 9 0 , we investigate the extent of this problem in finite samples, first under hypothetical conditions that follow Assumptions 1 and 2 in § 4·1, and under certain deviations from Assumption 1 in § 4·2.
S  4·1. Numerical results under both latent ignorability and compound exclusion
In each of the 12 conditions of Table 1 , n=500 individuals are randomised to either the standard or the new treatment arm with pr(Z i =1)=0·5 and, independently, compliance covariates U i are simulated as Bernoulli random variables with probability U 9 . Outcomes Y i are simulated from normal distributions with standard deviation equal to two, conditionally on covariates U i and treatment assignment arms Z i . The parameters that, for simplicity, we fix across experimental conditions are (i) the average outcomes for never-takers and compliers at the standard treatment arm, Y 9 0,0 =0, which equals Y 9 0,1 by Assumption 2, and Y 9 1,0 =3 respectively, and (ii) their response probabilities at the new treatment arm R 9 0,1 =R 9 1,1 =0·5, for simplicity. The parameters that we vary are (iii) the proportion of never-takers, that is 1−U 9 ; (iv) the average outcome effect for compliers, that is Y 9 1,1 −Y 9 1,0 =0 or 1; (v) the response probability for the compliers at the standard treatment arm; that is R 9 1,0 =0·5 gives ignorable nonresponse, i.e. missing at random, or R 9 1,0 =0·8, which gives nonignorable nonresponse, i.e. not missing at random. In each case we report the induced value, Y 9 1 −Y 9 0 , and the ratio of expected observable outcome to true, marginal expected outcome in the standard treatment arm, Y 9 obs 0 /Y 9 0 , as a measure of overall deviation from ignorability within arm z=0. Table 1 reports coverage rates of nominal 95% confidence intervals for Y 9 1 −Y 9 0 , and mean squared errors for estimators calculated using (i) the new procedure based on the normal approximation (3·4), labelled IV because it uses a generalisation of the instrumental variables procedure as derived by Angrist et al. (1996) , and (ii) the respondentbased intention-to-treat statistic (2·3) with a two-sample t confidence interval, labelled obs. For the special case where the treatment effect is zero within both never-takers and compliers, coverage rates for the null value are also reported using the following: 'astreated', which compares respondents based on treatment actually received, {Y i :
, using a two-sample t confidence interval; and 'per-protocol', which only considers respondents who adhered to protocol in the study and compares them based on treatment received, {Y i :
, using a twosample t confidence interval. Simulations reported in Table 1 are calculated over 10 000 datasets for each experimental condition, to ensure a standard error for the coverage rates no larger than 0·5%.
The as-treated procedure grossly undercovers the true null values, and the per protocol procedure is nearly as dreadful.
In the special case where the outcomes are missing at random, both IV and obs Table 1 . Inference for Y 9 1 −Y 9 0 under latent ignorability and compound exclusion restriction: coverage of nominal 95% intervals and mean squared error
Asymptotically, the properties of the procedures are not exactly invariant in location shifts of Y 9 1,1 −Y 9 1,0 . , missing at random; , not missing at random give good coverage. Also, since in this case noncompliance is not critically important, the efficiency that can be gained by capitalising on the compound exclusion restriction with our procedure trades off against the uncertainty about the various additional components that the new procedure estimates, as the mean squared errors indicate.
When, however, the missing outcome mechanism, induced by latent ignorability, is not ignorable, obs considerably undercovers the intention-to-treat effect, even when it is zero, with decreasing coverage as the proportion of never-takers (1−U 9 ) increases, and is inaccurate even with 80% compliance. In contrast, IV maintains adequate coverage in this case. Moreover, as suggested by the mean squared errors in these settings, IV can have substantially better overall accuracy relative to obs under nonignorability.
4·2. Numerical results with deviations from Assumption 1
In Table 2 we compare IV to obs with certain deviations from the latent ignorability of Assumption 1. We only simulate results here under the null hypothesis and under compound exclusion, so we first generate treatment assignments Z i , compliance covariates U i and outcomes Y i conditional on Z i and U i , as in the conditions of Table 1 for the null hypothesis. Then, response indicators R i are generated as in the six conditions of H 0 of Table 1 , for each combination of U i and Z i , except for the group of compliers in the standard treatment arm. For this group, we create deviations from Assumption 1 by generating response indicators R i independently of outcomes Y i conditionally on a covariate G i imperfectly correlated with U i . Note that Y i (0) is a covariate in the sense that it does not change with assignment, and so, for simplicity, we choose G i to be the indicator for whether or not Y i (0) exceeds the population average outcome for compliers at z=0, Y 9 1,0 . We generate R i independently of Y i conditionally on G i and with probabilities
The odds ratio r)p 1 (1−p 0 )/{p 0 (1−p 1 )} is a simple measure of deviation from Assumption 1. The values of r and R 9 1,0 , the marginal response rate for compliers at z=0, determine the probabilities p 1 and p 0 by a simple relation. We take the parameters in Intention-to-treat analysis Assumption 1 holds when r=1; see Table 1 . Table 2 as in the null hypothesis of Table 1 for U 9 , R 9 u,z and Y 9 u,z , but with r=1 2 , 3 4 , 4 3 and 2, to represent deviations ranging from half to twice the odds for response for above average versus below average compliers at standard treatment. Sample sizes and number of replications for each condition are as in Table 1 .
For conditions with R 9 1,0 =0·5, as with Table 1 , IV and obs are practically comparable to each other, although they both experience some bias for the situations with most extreme deviations from Assumption 1, r=1 2 and r=2. When the compliance covariate is associated with missingness, represented by the conditions with R 9 1,0 =0·8, we have two cases. First, values of r<1 generate here deviations in the direction opposite to the bias that is apparent to an investigator who has knowledge of the compliance covariates U i but not of G i . Secondly, values of r>1 generate deviations in the same direction as the bias generated by U i alone. Under the small deviations of the first type, r<1, in Table 2 , IV is relatively robust, and there is some cancellation of the bias of obs relative to Table 1 . Under the deviations of the second type, r>1, the obs procedure performs notably poorly, whereas IV performs quite well.
These observations also partly indicate what is expected when small deviations from Assumption 1 exist in more than one cell defined by (U, Z). If these deviations are mostly in one direction, the performances of IV and obs will either become more comparable or will further favour IV, relative to analogous cases where Assumption 1 holds. In more likely cases, where small deviations from Assumption 1 can be in different directions for different cells defined by (U, Z), then generally there will be a smaller overall component of additional bias either to cancel or further increase the bias that is due to U i alone. In these cases, the comparisons between IV and obs are expected to be more analogous to those under Assumption 1.
More generally, in practice, the comparison between IV and obs depends on the unknown, underlying parameter values. In a given study, such a simulation can be con-Intention-to-treat analysis
We may now use empirical estimates for the right-hand side of (5·2) to estimate the survival curve S 1,0 (y). Define the stochastic processes Under a mild regularity condition, a uniformly consistent estimator for S 1,0 (y) is S C 1,0 (y)=exp
where n 0 , n 1 are the numbers of individuals randomised to standard and new treatment arm respectively. An outline of the proof is given in the Appendix. This result establishes identifiability of the intention-to-treat survival curves (5·1) under latent ignorability and compound exclusion even in situations where the intention-to-treat Kaplan-Meier estimators are inconsistent.
F 
An alternative approach to the analytical methods discussed here could be to construct bounds for the treatment effect (Robins, 1989; Manski, 1990; Balke & Pearl, 1997) . The least favourable bounds are not generally very informative, e.g. Imbens & Rubin (1997) , and some additional subject-matter constraints typically are needed to interpret the data from such a study using this approach, e.g. Robins & Greenland (1996) . A more general approach is to study sensitivity of the results to deviations from the posited assumptions, e.g. Rosenbaum & Rubin (1983) , where the extreme results correspond to bounds.
Our methods, discussed for binary observed compliance for each subject in the new treatment arm, can be directly extended to allow for such compliance behaviour in the standard treatment arm as well, simply by extending Assumptions 1 and 2. For situations where all-or-none observed compliance is not realistic, some further assumptions will be required to address this problem. Barnard et al. (1998) describe a template for applying the ideas presented here to a large social science dataset.
